UC Davis-Enabled Startup Delix Therapeutics Secures $70 Million in Series A Funding
By Neelanjana Gautam UC Davis-enabled neuroscience startup Delix Therapeutics recently closed a $70 million Series A funding round. Co-founded by David E. Olson, associate professor in the Department of Chemistry and the Department of Biochemistry & Molecular Medicine, the preclinical startup is focused on developing safe, non-hallucinogenic, take-home medications for patients suffering from neuropsychiatric illnesses. […]

